Last reviewed · How we verify
Bortezomib-Melphalan
Bortezomib inhibits the proteasome to trigger cancer cell death, while melphalan is an alkylating agent that damages DNA in cancer cells.
Bortezomib inhibits the proteasome to trigger cancer cell death, while melphalan is an alkylating agent that damages DNA in cancer cells. Used for Multiple myeloma (induction therapy in phase 3 trials).
At a glance
| Generic name | Bortezomib-Melphalan |
|---|---|
| Sponsor | University Hospital, Toulouse |
| Drug class | Proteasome inhibitor + alkylating agent combination |
| Target | Proteasome (bortezomib); DNA (melphalan) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This combination pairs bortezomib, a proteasome inhibitor that prevents degradation of pro-apoptotic proteins and causes accumulation of misfolded proteins in cancer cells, with melphalan, a nitrogen mustard alkylating agent that cross-links DNA and induces cell death. The combination is designed to enhance cytotoxicity in multiple myeloma and other hematologic malignancies through complementary mechanisms.
Approved indications
- Multiple myeloma (induction therapy in phase 3 trials)
Common side effects
- Peripheral neuropathy
- Myelosuppression
- Nausea and vomiting
- Fatigue
- Infection
Key clinical trials
- Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older (PHASE2)
- Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (PHASE2)
- HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib (PHASE2)
- UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (PHASE3)
- Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) (PHASE3)
- Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (PHASE3)
- Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma (PHASE2)
- Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bortezomib-Melphalan CI brief — competitive landscape report
- Bortezomib-Melphalan updates RSS · CI watch RSS
- University Hospital, Toulouse portfolio CI